7 results on '"Szymonifka, Jackie"'
Search Results
2. Measurement of Novel Biomarkers to Predict Chronic Heart Failure Outcomes and Left Ventricular Remodeling
- Author
-
Motiwala, Shweta R., Szymonifka, Jackie, Belcher, Arianna, Weiner, Rory B., Baggish, Aaron L., Gaggin, Hanna K., Bhardwaj, Anju, and Januzzi, Jr., James L.
- Published
- 2014
- Full Text
- View/download PDF
3. Prognostic Significance of Treatment-Induced Pathologic Necrosis in Extremity and Truncal Soft Tissue Sarcoma after Neoadjuvant Chemoradiotherapy
- Author
-
Mullen, John T., Hornicek, Francis J., Harmon, David C., Raskin, Kevin A., Chen, Yen-Lin, Szymonifka, Jackie, Yeap, Beow Y., Choy, Edwin, DeLaney, Thomas F., and Nielsen, G. Petur
- Subjects
Male ,Torso ,Extremities ,Sarcoma ,Soft Tissue Neoplasms ,Chemoradiotherapy ,Histiocytoma, Malignant Fibrous ,Middle Aged ,Prognosis ,Article ,Disease-Free Survival ,Liposarcoma, Myxoid ,Neoadjuvant Therapy ,Cohort Studies ,Necrosis ,Sarcoma, Synovial ,Treatment Outcome ,Humans ,Female ,Neoplasm Grading ,Retrospective Studies - Abstract
Histologic response to chemotherapy has been shown to be an independent prognostic factor in patients with osteosarcoma and Ewing sarcoma. However, in patients with soft tissue sarcoma (STS), the prognostic impact of histologic response to chemotherapy is less clear. In the current study, the authors sought to determine the prognostic significance of treatment-induced pathologic necrosis in patients receiving neoadjuvant chemoradiotherapy for STS.Between 1989 and 2011, a total of 113 patients with grade 2 or 3 (graded according to the National Cancer Institute grading system using 3 tiers) extremity or truncal STS were identified who received neoadjuvant interdigitated chemoradiotherapy according to protocol followed by surgery. The extent of tumor necrosis in the resected specimens was quantified and correlated with outcome.The median tumor necrosis rate was 90%, and 103 patients (91%) received all 3 cycles of planned neoadjuvant chemotherapy. The likelihood of achieving ≥95% necrosis was not related to the number of preoperative cycles of chemotherapy received but was found to be related to tumor histology (62% for malignant fibrous histiocytoma vs 0% for synovial sarcoma [P.001]; 56% for myxoid liposarcoma vs 0% for synovial sarcoma [P = .002]). At a median follow-up of 6 years, there were no statistically significant differences noted in the 5-year local control, disease-specific survival, and overall survival rates for patients with ≥95% necrosis (50 patients; 44%) and95% necrosis (63 patients; 56%), even when stratifying by histology.In a homogeneous population of patients with high-grade extremity and truncal STS who were treated with neoadjuvant chemoradiotherapy, the extent of pathologic tumor necrosis did not correlate with outcome.
- Published
- 2014
4. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
- Author
-
Motiwala, Shweta R., Szymonifka, Jackie, Belcher, Arianna, Weiner, Rory B., Baggish, Aaron L., Sluss, Patrick, Gaggin, Hanna K., Bhardwaj, Anju, and Januzzi, James L.
- Subjects
- *
GALECTINS , *HEART failure patients , *HEART failure treatment , *BIOMARKERS , *HEART fibrosis , *BRAIN natriuretic factor , *CARDIAC contraction - Abstract
Aims Galectin-3 is a prognostic heart failure (HF) biomarker that may mediate cardiac fibrosis. We examined the value of serial galectin-3 measurement for prognosis and response to therapy in chronic HF. Methods and results A total of 151 subjects with LV systolic dysfunction (LVSD) were followed through 908 visits over 10 ± 3 months. The amount of time spent with a galectin-3 level ≤ 20.0 ng/mL and changes between baseline and subsequent values were considered across visits, and used to assess risk for adverse cardiovascular (CV) events and associations with LV remodelling. Medication effects on galectin-3 were examined. Median galectin-3 values at baseline, 3 months, and 6 months were higher in patients with CV events (21.7 vs. 18.4 ng/mL, P = 0.03; 21.7 vs. 16.5 ng/mL, P = 0.03; 23.2 vs. 16.0 ng/mL, P = 0.007). Galectin-3 concentration changed in 35.2% of subjects during study procedures; time spent at ≤ 20.0 ng/mL was significantly associated with a lower rate of CV events, independently predicted fewer CV events even adjusted for relevant variables including study allocation, NT-proBNP, and renal function [odds ratio (OR) = 0.90; P = 0.05], and predicted increase in LV ejection fraction (OR = 1.20; P = 0.04). Serial galectin-3 measurement at 6 months added prognostic value beyond the baseline level (P = 0.02). There were no significant effects of medications on galectin-3 levels. Conclusion In chronic HF due to LVSD, serial galectin-3 measurement adds incremental prognostic information and predicts LV remodelling. In this study, HF therapies had no clear effects on galectin-3 levels. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
5. β-Catenin Mutation Status and Outcomes in Sporadic Desmoid Tumors.
- Author
-
Mullen, John T., DeLaney, Thomas F., Rosenberg, Andrew E., Le, Long, Iafrate, A. John, Kobayashi, Wendy, Szymonifka, Jackie, Yeap, Beow Y., Chen, Yen‐Lin, Harmon, David C., Choy, Edwin, Yoon, Sam S., Raskin, Kevin A., Hornicek, Francis J., and Nielsen, Gunnlauger P.
- Subjects
CHI-squared test ,CYTOSKELETAL proteins ,GENES ,GENETIC mutation ,RESEARCH funding ,SURVIVAL analysis (Biometry) ,DISEASE relapse ,DATA analysis software ,DESCRIPTIVE statistics ,CONNECTIVE tissue tumors ,GENETICS ,PROGNOSIS - Abstract
Background. Mutations in the gene-encoding β-catenin, CTNNB1, are highly prevalent in sporadic desmoid tumors and may predict the risk for recurrence. We sought to determine the prevalence of CTNNB1 mutations in a large cohort of sporadic desmoids tumors and to determine whether CTNNB1 mutation status correlates with disease outcome. Methods. Single-base extension genotyping of the CTNNB1 gene was performed on 145 sporadic, paraffin-embedded desmoid tumor specimens. Correlation of mutation status with outcome was performed on a subset of 115 patients who underwent macroscopically complete surgical resection. Results. CTNNB1 mutations were detected in 106 of 145 (73%) tumor specimens and in 86 of 115 (75%) specimens from patients who underwent curative-intent surgical resection, including discrete mutations in the following codons of CTNNB1 exon 3: T41A (46%), S45F (25%), S45P (1.7%), and S45C (0.9%). Desmoid tumors of the superficial trunk were significantly less likely to harbor CTNNB1 mutations than tumors located elsewhere, but none of the other examined clinicopathologic factors were found to be associated with CTNNB1 mutation status. At a median follow-up of 31 months, 5-year recurrence-free survival was slightly, although not statistically significantly, worse for patients with β-catenin-mutated tumors than for those with wild-type tumors (58% vs. 74%, respectively). The specific CTNNB1 codon mutation did not correlate with the risk for recurrence. Conclusion. CTNNB1 mutations are indeed common in sporadic desmoid tumors. However, our study did not detect a statistically significant difference in recurrence risk according to either the CTNNB1 mutation status or the specific CTNNB1 mutation. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
6. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
- Author
-
Waheed, Sarah, Shaughnessy, John D., van Rhee, Frits, Alsayed, Yazan, Nair, Bijay, Anaissie, Elias, Szymonifka, Jackie, Hoering, Antje, Crowley, John, and Barlogie, Bart
- Subjects
MULTIPLE myeloma treatment ,CYTOGENETICS ,GENE expression ,PROGNOSIS ,THALIDOMIDE - Abstract
BACKGROUND: Myeloma survival varies markedly with International Staging System classification, presence of cytogenetic abnormalities, and, especially, gene expression profiling-based risk and delTP53 status, whose collective impact has not been examined in the context of specific therapies. METHODS: The authors examined overall survival (OS), event-free survival (EFS), and complete response duration (CRD) in Total Therapy 2 with randomization to a control or thalidomide arm and in Total Therapy 3 with added bortezomib. Among 612 patients with complete data sets, multivariate analyses were used to investigate the relative contributions to OS, EFS, and CRD of International Staging System stage, cytogenetic abnormalities, and gene expression profiling-derived risk and delTP53 status, in the context of the 3 Total Therapy regimens. RESULTS: Whereas gene expression profiling risk segregated outcomes within all 3 International Staging System stages, International Staging System 3 conferred inferior prognosis only in low-risk myeloma, whereas the grave prognosis of high-risk disease was International Staging System-independent. After adjusting for gene expression profiling-defined high risk and delTP53 in multivariate analysis, International Staging System 3 and cytogenetic abnormalities both retained independent adverse implications for OS, EFS, and CRD. Among the 86% with low-risk disease, cytogenetic abnormalities and delTP53 both affected all 3 endpoints negatively, whereas the International Staging System 3 effect was limited to OS. Total Therapy 3 improved survival outcomes beyond results obtained with Total Therapy 2. CONCLUSIONS: In the genomic era, standard laboratory variables, such as International Staging System stage and presence of cytogenetic abnormalities, continue to impact survival after adjusting for gene expression profiling risk and delTP53 status, providing a basis for stratification in our current practice of gene expression profiling risk-based treatment assignment. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
7. Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols.
- Author
-
Nair, Bijay, Waheed, Sarah, Szymonifka, Jackie, Shaughnessy Jr, John D, Crowley, John, and Barlogie, Bart
- Subjects
MULTIPLE myeloma ,GENOTYPE-environment interaction ,IMMUNOGLOBULIN genes ,GENETICS ,PHENOTYPES ,PROGNOSTIC tests - Abstract
The article focuses on the immunoglobulin (Ig) isotypes in multiple myeloma. It highlights the Ig heavy and light chain isotypes prognostically relevant baseline laboratory features. It also features the protocols for newly diagnosed patients with symptomatic or progressive disease. Various phenotypes with baseline prognostic features were also discussed by the author.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.